Wolters Kluwer repurchased 499 of its ordinary shares between October 29 and November 4, 2026, spending €0.04 million at an average price of €85.06 per share. This is part of a larger 2026 share buyback program aiming to repurchase shares worth up to €500 million. So far in 2026, the company has bought back 3,888,500 shares totaling €264.3 million. The repurchased shares are held as treasury shares and will be used for capital reduction through share cancellation. The company continues to engage a third party for further buybacks until December 28, 2026, within legal limits.
Wolters Kluwer's recent share buyback activity provides context for readers interested in market movements. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 05, 2026 15:02 WIB: out of 150 priced US stocks, 43 rose and 98 fell. Notable movers include CRSR at USD 13.01 with a 1-day change of +5.69%, UMC at USD 15.20 down 5.35%, and SONY at USD 27.30 up 5.20%.
Lorenz Snacks has introduced a fleet of four autonomous, electric vehicles from Einride at its production site in Neunburg vorm Wald, Germany. These vehicles will handle in-plant transport of goods and materials, replacing diesel trucks and significa...
Futu Holdings Limited will announce its financial results for the third quarter ending September 30, 2026, on November 19 before U.S. market open. The company will host a live earnings conference call at 7:30 AM ET (8:30 PM Beijing/Hong Kong time) th...
UBS Group AG notified Bang & Olufsen A/S that its shareholding and voting rights exceeded 5% as of October 30, 2026, but fell below 5% by November 2, 2026. As of November 2, UBS held 4.66% of Bang & Olufsen's total shares and voting rights. This chan...
T-Therapeutics secured $133 million in an oversubscribed Series B funding round led by Advent Life Sciences and British Business Bank to develop its first-in-class TCR-CD3 bispecific therapies targeting cancer and autoimmune diseases. The funds will ...
Siemens Healthineers has begun separating its in vitro diagnostics business into a standalone company named Olyrian Diagnostics, expected to complete by mid-2028. This move aims to give the diagnostics unit a distinct market presence while continuing...
